NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

The Manufacturing Import Authorization (MIA) license for the facility in Sawston, UK, is tied to the specific location, equipment, and processes described in the license. If Northwest Biotherapeutics (NWBO) owns the equipment, holds the long-term lease for the building, and their vaccine, DCVax, is central to the facility's purpose, then the license is closely associated with that setup.

Here’s a breakdown of how this situation likely works:

1. Ownership and Control: Since NWBO owns the equipment and holds the lease, they retain significant control over the facility. The MIA license is granted based on specific qualifications of the facility, equipment, and processes. Advent BioServices, as the holder of the MIA, would not be able to transfer the license to another facility without regulatory approval, which typically requires inspections and meeting new qualifications.

2. License Tied to Facility: The MIA license is specific to the location and cannot simply be moved to another site. If Advent BioServices were acquired, the new owner would not be able to "take the license with them" to another manufacturing facility without undergoing the process of obtaining a new MIA for the new facility.

3. NWBO’s Leverage: Since NWBO owns the equipment and has the lease, it would be challenging for Advent to operate independently of NWBO in the current facility. If Advent’s ownership changes, NWBO's continued cooperation would likely be necessary for operations to proceed as the equipment and facility are integral to the license's validity.

4. Regulatory and Contractual Considerations: The relationship between Advent and NWBO is likely governed by contractual agreements. These agreements, along with regulatory requirements, would play a significant role in determining what happens if Advent were acquired.

In summary, while the MIA license is technically held by Advent BioServices, its practical application is deeply tied to the specific facility, equipment, and processes owned or controlled by NWBO. This would make it difficult for an acquiring entity to simply relocate or reassign the license without regulatory approval and NWBO's cooperation.